文献速递系统性红斑狼疮

B细胞Tetherin流式细胞术检测预测系统性红斑狼疮临床特征与复发

B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2020-04-03

本研究验证了一种B细胞特异性I型干扰素(IFN)检测——记忆B细胞表面Tetherin(CD317)流式细胞术。在发现队列(156例SLE、30例RA、25例健康对照)中,记忆B细胞Tetherin与SLE诊断、利妥昔单抗治疗后浆细胞样细胞数及BILAG 2004评分相关;在纵向验证队列(80例SLE)中,其可预测未来临床复发(HR 2.29,95%CI 1.01-4.64,P=0.022)。

要点

  • 记忆B细胞Tetherin与SLE诊断相关(SLE vs 健康对照效应量0.11,P=0.003;SLE vs RA效应量0.17,P<0.001)。
  • 记忆B细胞Tetherin与利妥昔单抗治疗患者浆细胞样细胞数相关(R=0.38,P=0.047)。
  • 记忆B细胞Tetherin预测SLE复发(HR 2.29,95%CI 1.01-4.64,P=0.022),优于其他细胞亚群或全血检测。

核心结论

  • 记忆B细胞表面Tetherin作为一种B细胞特异性I型IFN检测,与SLE诊断和疾病活动度相关,并能预测临床复发。

研究设计与样本

  • 体外验证Tetherin(CD317)流式细胞术检测,并在发现队列(156例SLE、30例RA、25例健康对照)和纵向验证队列(80例SLE)中进行临床评估。

主要发现

  • 体外实验显示I型IFN应答基因与细胞表面Tetherin在所有免疫细胞亚群中呈细胞特异性和剂量依赖关系。
  • 记忆B细胞Tetherin与SLE诊断关联最强(SLE vs 健康对照效应量0.11,P=0.003;SLE vs RA效应量0.17,P<0.001)。
  • 记忆B细胞Tetherin与利妥昔单抗治疗患者浆细胞样细胞数相关(R=0.38,P=0.047),并与BILAG 2004评分相关。
  • 在验证队列中,记忆B细胞Tetherin预测未来临床复发(HR 2.29,95%CI 1.01-4.64,P=0.022)。

关键数值与推荐

  • 记忆B细胞Tetherin与SLE诊断的效应量:SLE vs 健康对照0.11(P=0.003),SLE vs RA 0.17(P<0.001)。
  • 与浆细胞样细胞数的相关系数R=0.38(P=0.047)。
  • 预测复发的风险比HR 2.29(95%CI 1.01-4.64,P=0.022)。

临床怎么用

  • 记忆B细胞Tetherin流式检测或可作为评估SLE疾病活动和预测复发的辅助工具。

局限性

  • 发现队列和验证队列样本量有限(分别为156例和80例SLE患者),需进一步扩大验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type I interferon (IFN) responses are broadly associated with autoimmune diseases, including systemic lupus erythematosus (SLE). Given the cardinal role of autoantibodies in SLE, this study was undertaken to investigate whether the findings of a B cell-specific IFN assay correlate with SLE activity. METHODS: B cells and peripheral blood mononuclear cells (PBMCs) were stimulated with type I IFN and type II IFN. Gene expression was analyzed, and the expression of pathway-related membrane proteins was determined. A flow cytometry assay for tetherin (CD317), an IFN-induced protein ubiquitously expressed on leukocytes, was validated in vitro and then clinically against SLE diagnosis, plasmablast expansion, and the British Isles Lupus Assessment Group (BILAG) 2004 score in a discovery cohort (n = 156 SLE patients, 30 rheumatoid arthritis [RA] patients, and 25 healthy controls). A second, longitudinal validation cohort of 80 SLE patients was also evaluated for flare prediction. RESULTS: In vitro, a close cell-specific and dose-response relationship between type I IFN-responsive genes and cell surface tetherin was observed in all immune cell subsets. Tetherin expression on multiple cell subsets was selectively responsive to stimulation with type I IFN compared to types II and III IFNs. In patient samples from the discovery cohort, memory B cell tetherin showed the strongest associations with diagnosis (SLE:healthy control effect size 0.11 [P = 0.003]; SLE:RA effect size 0.17 [P < 0.001]), plasmablast numbers in rituximab-treated patients (R = 0.38, P = 0.047), and BILAG 2004. These associations were equivalent to or stronger than those for IFN score or monocyte tetherin. Memory B cell tetherin was found to be predictive of future clinical flares in the validation cohort (hazard ratio 2.29 [95% confidence interval 1.01-4.64]; P = 0.022). CONCLUSION: Our findings indicate that memory B cell surface tetherin, a B cell-specific IFN assay, is associated with SLE diagnosis and disease activity, and predicts flares better than tetherin on other cell subsets or whole blood assays, as determined in an independent validation cohort.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. El-Sherbiny YM, Md Yusof MY, Psarras A, et al. B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020. PMID: 31804007. doi:10.1002/art.41187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。